Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M98,474Revenue (TTM) $M17,837Net Margin (%)26.3Altman Z-Score1.1
Enterprise Value $M143,696EPS (TTM) $10.8Operating Margin %-12.3Piotroski F-Score6
P/E(ttm)23.2Beneish M-Score-2.5Pre-tax Margin (%)-20.1Higher ROA y-yY
Price/Book1.410-y EBITDA Growth Rate %--Quick Ratio0.9Cash flow > EarningsY
Price/Sales5.45-y EBITDA Growth Rate %3.6Current Ratio1.0Lower Leverage y-yY
Price/Free Cash Flow20.5y-y EBITDA Growth Rate %355ROA % (ttm)3.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)5.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M396ROIC % (ttm)-1.1Gross Margin Increase y-yY

Gurus Latest Trades with AGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AGNSeth Klarman 2016-03-31 Buy 6.72%$266.3 - $312.5
($286.72)
$ 248.95-13%New holding1,721,587
AGNSteve Mandel 2016-03-31 Buy 2.39%$266.3 - $312.5
($286.72)
$ 248.95-13%New holding1,789,239
AGNLeon Cooperman 2016-03-31 Reduce-1.5%$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -28.21%561,265
AGNGeorge Soros 2016-03-31 Reduce-1.29%$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -60.79%143,277
AGNWallace Weitz 2016-03-31 Add1.04%$266.3 - $312.5
($286.72)
$ 248.95-13%Add 55.34%304,722
AGNDavid Tepper 2016-03-31 Add0.61%$266.3 - $312.5
($286.72)
$ 248.95-13%Add 86.07%279,109
AGNFirst Eagle Investment 2016-03-31 Reduce-0.23%$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -44.51%371,770
AGNJohn Paulson 2016-03-31 Reduce-0.22%$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -2.07%5,418,300
AGNPrivate Capital 2016-03-31 Reduce-0.17%$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -2.58%161,728
AGNVanguard Health Care Fund 2016-03-31 Add0.13%$266.3 - $312.5
($286.72)
$ 248.95-13%Add 2.05%11,187,547
AGNDavid Einhorn 2016-03-31 Add0.12%$266.3 - $312.5
($286.72)
$ 248.95-13%Add 6.63%437,200
AGNRuane Cunniff 2016-03-31 Reduce-0.11%$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -5.55%1,025,555
AGNJoel Greenblatt 2016-03-31 Reduce-0.09%$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -65.99%14,367
AGNRon Baron 2016-03-31 Add0.02%$266.3 - $312.5
($286.72)
$ 248.95-13%Add 132.11%27,278
AGNMario Gabelli 2016-03-31 Add0.01%$266.3 - $312.5
($286.72)
$ 248.95-13%Add 18.90%39,798
AGNKen Fisher 2016-03-31 Reduce$266.3 - $312.5
($286.72)
$ 248.95-13%Reduce -2.45%3,225
AGNSteve Mandel 2015-12-31 Sold Out -2.99%$253.04 - $322.49
($298.52)
$ 248.95-17%Sold Out0
AGNJohn Paulson 2015-12-31 Reduce-2.4%$253.04 - $322.49
($298.52)
$ 248.95-17%Reduce -22.97%5,532,600
AGNDavid Einhorn 2015-12-31 Buy 2.35%$253.04 - $322.49
($298.52)
$ 248.95-17%New holding410,000
AGNJulian Robertson 2015-12-31 Sold Out -2.17%$253.04 - $322.49
($298.52)
$ 248.95-17%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hilado Maria TeresaCFO 2016-06-02Buy661$241.572.6view
Basgoz NesliDirector 2016-05-11Sell459$225.110.11view
Basgoz NesliDirector 2015-12-07Sell2,300$312.96-20.8view
BISARO PAULExec Chairman 2015-08-24Buy1,000$297.42-16.67view
SAUNDERS BRENT LCEO and President 2015-08-21Buy1,000$301.94-17.91view
Basgoz NesliDirector 2015-06-09Sell2,200$297.89-16.8view
Meury WilliamSee Remarks 2014-11-26Sell4,550$269.14-7.91view
PAONESSA ALBERT IIIPresident Anda, Inc. 2014-09-08Sell6,642$230.497.53view
Hindman James M.EVP, Finance & Bus. Dev., CFO 2014-08-18Sell0$07.53view
Sherman Scott DExecutive Vice President, HR 2014-04-22Sell14,500$155.8259.06view

Press Releases about AGN :

Quarterly/Annual Reports about AGN:

News about AGN:

Articles On GuruFocus.com
Weitz Funds Comments on Allergan Jul 20 2016 
Ruane Cunniff Comments on Allergan Jul 13 2016 
Sequoia Fund Addresses Valeant, New Buys, Board Changes in 2nd Quarter Letter Jul 13 2016 
3 of Paul Singer's Top 5 Deals in 1st Quarter Involve Technology Stocks Jun 26 2016 
Steve Mandel Exits Position in Williams Companies in 1st Quarter Jun 24 2016 
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 
John Paulson Trims Time Warner Cable, Starwood Hotels May 18 2016 
Seth Klarman's 5 New Buys May 13 2016 
The PBM Empire Strikes Back May 10 2016 
Baron Funds Comments on Allergan plc May 06 2016 

More From Other Websites
Street Talk: Mondelez & more Jul 25 2016
Allergan Gets Positive Opinion For Its Truberzi For Irritable Bowel Syndrome With Diarrhoea... Jul 25 2016
Credit Suisse says Allergan's drug pipeline is 'underappreciated' Jul 25 2016
Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel... Jul 25 2016
Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel... Jul 25 2016
11:30 am Allergan announces the CHMP has adopted a Positive Opinion for TRUBERZI in the EU Jul 25 2016
Jim Cramer -- I Agree With the Analysts on Gap, Allergan Jul 25 2016
Why Traders Are Watching Tesla, SolarCity, Allergan & Other Stocks Today Jul 25 2016
Specialty Pharma: Earnings Better Be Good…or Else Jul 25 2016
Coverage initiated on Allergan by Credit Suisse Jul 25 2016
Investors scrap for Teva Pharmaceutical bonds Jul 22 2016
Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin Jul 21 2016
Amgen (AMGN) Stock Rises on 'Non-Inferior' Late-Stage Trial Results Jul 21 2016
Valeant & Endo: Imagining a World With No Drug Pricing Controversies Jul 21 2016
Amgen, Allergan biosimilar found as effective as Roche cancer drug Jul 21 2016
Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With... Jul 21 2016
[$$] Jury Acquits Former Johnson & Johnson Unit Execs of Felony Fraud Jul 20 2016
Weitz Funds Comments on Allergan Jul 20 2016
Weitz Funds' 2nd Quarter 2016 Value Fund Commentary Jul 20 2016
Wally Weitz's Partners Value Fund 2Q 2016 Quarterly Commentary Jul 20 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)